Candesartan cilexetil/nifedipine

Drug Profile

Candesartan cilexetil/nifedipine

Alternative Names: BAY-98-7106; Candesartan cilexetil/nifedipine GITS; Nifedipine GITS/candesartan cilexetil; Nifedipine/candesartan-cilexetil

Latest Information Update: 04 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Antihypertensives; Benzimidazoles; Dihydropyridines; Heart failure therapies; Ischaemic heart disorder therapies; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Essential hypertension

Most Recent Events

  • 13 Dec 2016 Bayer withdrew a phase III trial prior to enrolment for Essential hypertension in Italy (NCT02047019)
  • 29 Sep 2016 Bayer completes a Phase-III trial in Essential hypertension in Italy and Germany (PO) (EudraCT2012-4857-10)
  • 03 Sep 2015 Candesartan cilexetil/nifedipine is still in phase-II development for Essential hypertension in Argentina, Brazil, Lithuania, Russia, South Africa, South Korea, Spain and Ukraine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top